Novel therapeutic strategies in the treatment of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2017-07, Vol.9 (7), p.493-511
Main Authors: Oualla, Karima, El-Zawahry, Heba M., Arun, Banu, Reuben, James M., Woodward, Wendy A., Gamal El-Din, Heba, Lim, Bora, Mellas, Nawfel, Ueno, Naoto T., Fouad, Tamer M.
Format: Article
Language:English
Subjects:
Anthracycline
Breast cancer
Cancer therapies
Chemotherapy
Epidermal growth factor
ErbB-2 protein
Estrogen receptors
Patients
Progesterone
Reviews
Taxanes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3
cites cdi_FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3
container_end_page 511
container_issue 7
container_start_page 493
container_title Therapeutic Advances in Medical Oncology
container_volume 9
creator Oualla, Karima
El-Zawahry, Heba M.
Arun, Banu
Reuben, James M.
Woodward, Wendy A.
Gamal El-Din, Heba
Lim, Bora
Mellas, Nawfel
Ueno, Naoto T.
Fouad, Tamer M.
description Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.
doi_str_mv 10.1177/1758834017711380
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_be71e70bf65c4817a952c1003a72f5f3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1758834017711380</sage_id><doaj_id>oai_doaj_org_article_be71e70bf65c4817a952c1003a72f5f3</doaj_id><sourcerecordid>1921136654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EoqVw54QiceES8Nhx7FyQUMVHpapc4GxNnEnqVTZebGel_nu8bCltJU4ez7zzeMYvY6-BvwfQ-gNoZYxseIkBpOFP2OkhVRupuqf34hP2IqUN523btPw5OxFGgy5tp-zqKuxprvI1RdzRmr2rUo6YafKUKr8cKlWOhHlLS67CWC5-N1O90ITZ76nqSzHlyuHiKL5kz0acE726Pc_Yzy-ff5x_qy-_f704_3RZOyVMrqURZgSpRjV0HAcNBLqTygFJXkqdAjItQOv6QTgnkRAUqr7rVU9ucIM8YxdH7hBwY3fRbzHe2IDe_kmEOFmMZZmZbE8Fr3k_tso1BjR2SjjgXKIWoxplYX08snZrv6XBlT0jzg-gDyuLv7ZT2FuluCijFsC7W0AMv1ZK2W59cjTPuFBYk4VOFHfaVjVF-vaRdBPWuJSvskI2QiqlwRQVP6pcDClFGu-GAW4PxtvHxpeWN_eXuGv463QR1EdBwon-vfpf4G92ZrWs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2342355718</pqid></control><display><type>article</type><title>Novel therapeutic strategies in the treatment of triple-negative breast cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Sage Journals GOLD Open Access 2024</source><creator>Oualla, Karima ; El-Zawahry, Heba M. ; Arun, Banu ; Reuben, James M. ; Woodward, Wendy A. ; Gamal El-Din, Heba ; Lim, Bora ; Mellas, Nawfel ; Ueno, Naoto T. ; Fouad, Tamer M.</creator><creatorcontrib>Oualla, Karima ; El-Zawahry, Heba M. ; Arun, Banu ; Reuben, James M. ; Woodward, Wendy A. ; Gamal El-Din, Heba ; Lim, Bora ; Mellas, Nawfel ; Ueno, Naoto T. ; Fouad, Tamer M.</creatorcontrib><description>Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.</description><identifier>ISSN: 1758-8359</identifier><identifier>ISSN: 1758-8340</identifier><identifier>EISSN: 1758-8359</identifier><identifier>DOI: 10.1177/1758834017711380</identifier><identifier>PMID: 28717401</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Anthracycline ; Breast cancer ; Cancer therapies ; Chemotherapy ; Epidermal growth factor ; ErbB-2 protein ; Estrogen receptors ; Patients ; Progesterone ; Reviews ; Taxanes</subject><ispartof>Therapeutic Advances in Medical Oncology, 2017-07, Vol.9 (7), p.493-511</ispartof><rights>The Author(s), 2017</rights><rights>The Author(s), 2017. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2017 2017 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3</citedby><cites>FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502951/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2342355718?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,21966,25753,27853,27922,27924,27925,37012,37013,44590,44945,45333,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28717401$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oualla, Karima</creatorcontrib><creatorcontrib>El-Zawahry, Heba M.</creatorcontrib><creatorcontrib>Arun, Banu</creatorcontrib><creatorcontrib>Reuben, James M.</creatorcontrib><creatorcontrib>Woodward, Wendy A.</creatorcontrib><creatorcontrib>Gamal El-Din, Heba</creatorcontrib><creatorcontrib>Lim, Bora</creatorcontrib><creatorcontrib>Mellas, Nawfel</creatorcontrib><creatorcontrib>Ueno, Naoto T.</creatorcontrib><creatorcontrib>Fouad, Tamer M.</creatorcontrib><title>Novel therapeutic strategies in the treatment of triple-negative breast cancer</title><title>Therapeutic Advances in Medical Oncology</title><addtitle>Ther Adv Med Oncol</addtitle><description>Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.</description><subject>Anthracycline</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Estrogen receptors</subject><subject>Patients</subject><subject>Progesterone</subject><subject>Reviews</subject><subject>Taxanes</subject><issn>1758-8359</issn><issn>1758-8340</issn><issn>1758-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kU1v1DAQhi0EoqVw54QiceES8Nhx7FyQUMVHpapc4GxNnEnqVTZebGel_nu8bCltJU4ez7zzeMYvY6-BvwfQ-gNoZYxseIkBpOFP2OkhVRupuqf34hP2IqUN523btPw5OxFGgy5tp-zqKuxprvI1RdzRmr2rUo6YafKUKr8cKlWOhHlLS67CWC5-N1O90ITZ76nqSzHlyuHiKL5kz0acE726Pc_Yzy-ff5x_qy-_f704_3RZOyVMrqURZgSpRjV0HAcNBLqTygFJXkqdAjItQOv6QTgnkRAUqr7rVU9ucIM8YxdH7hBwY3fRbzHe2IDe_kmEOFmMZZmZbE8Fr3k_tso1BjR2SjjgXKIWoxplYX08snZrv6XBlT0jzg-gDyuLv7ZT2FuluCijFsC7W0AMv1ZK2W59cjTPuFBYk4VOFHfaVjVF-vaRdBPWuJSvskI2QiqlwRQVP6pcDClFGu-GAW4PxtvHxpeWN_eXuGv463QR1EdBwon-vfpf4G92ZrWs</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Oualla, Karima</creator><creator>El-Zawahry, Heba M.</creator><creator>Arun, Banu</creator><creator>Reuben, James M.</creator><creator>Woodward, Wendy A.</creator><creator>Gamal El-Din, Heba</creator><creator>Lim, Bora</creator><creator>Mellas, Nawfel</creator><creator>Ueno, Naoto T.</creator><creator>Fouad, Tamer M.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170701</creationdate><title>Novel therapeutic strategies in the treatment of triple-negative breast cancer</title><author>Oualla, Karima ; El-Zawahry, Heba M. ; Arun, Banu ; Reuben, James M. ; Woodward, Wendy A. ; Gamal El-Din, Heba ; Lim, Bora ; Mellas, Nawfel ; Ueno, Naoto T. ; Fouad, Tamer M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anthracycline</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Estrogen receptors</topic><topic>Patients</topic><topic>Progesterone</topic><topic>Reviews</topic><topic>Taxanes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oualla, Karima</creatorcontrib><creatorcontrib>El-Zawahry, Heba M.</creatorcontrib><creatorcontrib>Arun, Banu</creatorcontrib><creatorcontrib>Reuben, James M.</creatorcontrib><creatorcontrib>Woodward, Wendy A.</creatorcontrib><creatorcontrib>Gamal El-Din, Heba</creatorcontrib><creatorcontrib>Lim, Bora</creatorcontrib><creatorcontrib>Mellas, Nawfel</creatorcontrib><creatorcontrib>Ueno, Naoto T.</creatorcontrib><creatorcontrib>Fouad, Tamer M.</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Medical Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oualla, Karima</au><au>El-Zawahry, Heba M.</au><au>Arun, Banu</au><au>Reuben, James M.</au><au>Woodward, Wendy A.</au><au>Gamal El-Din, Heba</au><au>Lim, Bora</au><au>Mellas, Nawfel</au><au>Ueno, Naoto T.</au><au>Fouad, Tamer M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel therapeutic strategies in the treatment of triple-negative breast cancer</atitle><jtitle>Therapeutic Advances in Medical Oncology</jtitle><addtitle>Ther Adv Med Oncol</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>9</volume><issue>7</issue><spage>493</spage><epage>511</epage><pages>493-511</pages><issn>1758-8359</issn><issn>1758-8340</issn><eissn>1758-8359</eissn><abstract>Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>28717401</pmid><doi>10.1177/1758834017711380</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1758-8359
ispartof Therapeutic Advances in Medical Oncology, 2017-07, Vol.9 (7), p.493-511
issn 1758-8359
1758-8340
1758-8359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_be71e70bf65c4817a952c1003a72f5f3
source Open Access: PubMed Central; Publicly Available Content Database; Sage Journals GOLD Open Access 2024
subjects Anthracycline
Breast cancer
Cancer therapies
Chemotherapy
Epidermal growth factor
ErbB-2 protein
Estrogen receptors
Patients
Progesterone
Reviews
Taxanes
title Novel therapeutic strategies in the treatment of triple-negative breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A55%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20therapeutic%20strategies%20in%20the%20treatment%20of%20triple-negative%20breast%20cancer&rft.jtitle=Therapeutic%20Advances%20in%20Medical%20Oncology&rft.au=Oualla,%20Karima&rft.date=2017-07-01&rft.volume=9&rft.issue=7&rft.spage=493&rft.epage=511&rft.pages=493-511&rft.issn=1758-8359&rft.eissn=1758-8359&rft_id=info:doi/10.1177/1758834017711380&rft_dat=%3Cproquest_doaj_%3E1921136654%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c528t-3828f135f5d90ad71e17935c1e30828951e86116cbd2cc3aea15a5b9b5becdcd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2342355718&rft_id=info:pmid/28717401&rft_sage_id=10.1177_1758834017711380&rfr_iscdi=true